EGFR and lung carcinoma: Significant advances in the treatment and outcome of advanced EGFR-mutant lung cancer patients have been achieved with EGFR tyrosine kinase inhibitors (TKIs), especially for those patients with exon 19 deletion or L858R [3–5].